Because significant interleukin-2 (IL-2) release has been confirmed following gluten challenges in CeD patients with well-controlled GFD24, IL-2 is one of the most reliable CeD relevant CD4+ T cell activation markers. This evidence concerns the gene CD4 and cranioectodermal dysplasia.